Advertisement

Drugs

, Volume 67, Issue 13, pp 1917–1929 | Cite as

Telbivudine

  • Susan J. KeamEmail author
Adis Drug Profile

Abstract

  • ▲ Telbivudine, the unmodified L-enantiomer of the naturally occurring nucleoside D-thymidine, is a potent synthetic nucleoside analogue. It acts as a hepatitis B virus (HBV) polymerase inhibitor and preferentially inhibits HBV second strand (DNA-dependent) compared with first strand (RNA-dependent) DNA synthesis.

  • ▲ More telbivudine than lamivudine recipients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and similar proportions of telbivudine or lamivudine recipients with HBeAg-negative disease achieved a therapeutic response at 52 weeks in the large 2-year GLOBE trial. In a phase III trial in Chinese patients, greater reductions in serum HBV DNA occurred with telbivudine than lamivudine at 52 weeks.

  • ▲ Reductions in serum HBV DNA at 24 weeks were greater with telbivudine than adefovir in the 1-year switching trial. A lower residual viral load at 52 weeks was seen in patients who received telbivudine or who switched from adefovir to telbivudine at 24 weeks than in patients receiving adefovir.

  • ▲ In the 1-year lamivudine switching trial in patients with serum HBV DNA levels >3 log10 copies/mL despite having received prior treatment with lamivudine for a mean of ≈7 months, those randomised to telbivudine therapy achieved greater reductions in serum HBV DNA levels at 24 weeks than patients randomised to continue lamivudine therapy.

  • ▲ Telbivudine was generally well tolerated and most adverse events were of mild or moderate severity. The incidence of severe ALT flares with telbivudine was half that seen with lamivudine at both 52 and 104 weeks in the GLOBE trial.

Keywords

Lamivudine Adefovir HBeAg Seroconversion Telbivudine Switching Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The manuscript was reviewed by: E. Gane, NZ Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; J.-D. Jia, Liver Research Center, Beijing Friendship Hospital, Beijing, China; C.-L. Lai, University of Hong Kong, Hong Kong, PR China. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes based on any comments received were made on the basis of scientific and editorial merit.

References

  1. 1.
    Farrell GC, Teoh NC. Management of chronic hepatitis B viras infection: a new era of disease control. Intern Med J 2006 Feb; 36(2): 100–13PubMedCrossRefGoogle Scholar
  2. 2.
    Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 Oct; 45(4): 529–38PubMedCrossRefGoogle Scholar
  3. 3.
    European Medicines Agency. Sebivo: scientific discussion. [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/sebivo/H-713-en6.pdf [Accessed 2007 May 19]
  4. 4.
    Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drags 2006; 66(12): 1605–22; discussion 1623-4CrossRefGoogle Scholar
  5. 5.
    Buti M, Esteban R. Drags in development for hepatitis B. Drags 2005; 65(11): 1451–60CrossRefGoogle Scholar
  6. 6.
    Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004 Mar 11; 350(11): 1118–29PubMedCrossRefGoogle Scholar
  7. 7.
    Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25 Suppl. 1: 40–7PubMedCrossRefGoogle Scholar
  8. 8.
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B viras DNA level. JAMA 2006 Jan 4; 295(1): 65–73PubMedCrossRefGoogle Scholar
  9. 9.
    Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 Mar; 130(3): 678–86PubMedCrossRefGoogle Scholar
  10. 10.
    Robins GW, Scott LJ, Keating GM. Peginterferon-α-2a (40kD): a review of its use in the management of patients with chronic hepatitis B. Drags 2005; 65(6): 809–25CrossRefGoogle Scholar
  11. 11.
    Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B [published erratum appears in Drugs 1999; 58: 587]. Drugs 1999 Jul; 58(1): 101–41PubMedCrossRefGoogle Scholar
  12. 12.
    Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drags 2003; 63(20): 2215–34CrossRefGoogle Scholar
  13. 13.
    Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001 Jan; 45(1): 229–35PubMedCrossRefGoogle Scholar
  14. 14.
    Standring DN, Bridges EG, Placidi L, et al. Antiviral β-L-nucleosides specific for hepatitis B viras infection. Antivir Chem Chemother 2001; 12 Suppl. 1: 119–29PubMedGoogle Scholar
  15. 15.
    European Medicines Agency. Sebivo 600mg film-coated tablets: summary of prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/sebivo/H-713-PI-en.pdf [Accessed 2007 May 19]
  16. 16.
    Seifer M, Patty A, Dukhan D et al. Telbivudine (LDT) preferentially inhibits second (+) strand HBV DNA synthesis [abstract no. M935]. Gastroenterology 2005 May 16; 128 (4 Suppl. 2): 742–43. Plus poster presented at Digestive Disease Week; 2005 May 14–19; Chicago (IL)Google Scholar
  17. 17.
    Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 Aug; 129(2): 528–36PubMedGoogle Scholar
  18. 18.
    Bridges EG, Juodawlkis A, Faraj A, et al. Antiviral activity of β-L-thymidine and β-L-2′deoxycytidine in the woodchuck model of chronic hepatitis B infection [abstract no. 91]. Antiviral Res 2000 Jan; 46(1): 62Google Scholar
  19. 19.
    Delaney WEIV, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004 Oct; 48(10): 3702–10PubMedCrossRefGoogle Scholar
  20. 20.
    Lai CL, Leung NW, Teo EK, et al. Phase IIb extended-treatment trial of telbivudine vs lamivudine vs combination treatment in hepatitis B patients: two-year results [abstract no 320]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): A692Google Scholar
  21. 21.
    Seifer M, Patty A, Chapron C, et al. Genotypic analysis of patients with evaluable HBV DNA after 1 year of telbivudine therapy in the GLOBE Registration Trial [abstract no. 93]. Digestive Disease Week; 2007 May 19–24; Washington DCGoogle Scholar
  22. 22.
    Standring DN, Patty A, Chapron C, et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the international GLOBE trial [abstract no. S1781 plus poster]. Digestive Disease Week; 2007 May 19–24; Washington DCGoogle Scholar
  23. 23.
    Standring DN, Seifer M, Patty A, et al. HBV resistance determination from the telbivudine GLOBE registration trial [abstract no. 514]. J Hepatol 2006; 44 (2 Suppl.): S191CrossRefGoogle Scholar
  24. 24.
    Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of nextgeneration nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10(5): 625–33PubMedGoogle Scholar
  25. 25.
    Idenix Pharmaceuticals Inc. Tyzeka (telbivudine) tablets. US prescribing information [online]. Available from URL: https://www.tyzeka.com/pdf/TYZEKA_PI_l 1-3-06_TYZ_MPI_02_001.pdf [Accessed 2007 Jul 29]
  26. 26.
    Hu P, Jiang J, Wang H, et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006 Sep; 46(9): 999–1007PubMedCrossRefGoogle Scholar
  27. 27.
    Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004 Sep; 40(3): 719–26PubMedCrossRefGoogle Scholar
  28. 28.
    Zhou XJ, Lloyd DM, Chao GC, et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 2006 Mar; 46(3): 275–81PubMedCrossRefGoogle Scholar
  29. 29.
    Zhou XJ, Fielman B, Dubuc-Patrick G, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon alpha-2a or cyclosporine in healthy subjects [abstract no. 522]. J Hepatol 2006; 44 Suppl. 2: S194CrossRefGoogle Scholar
  30. 30.
    Zhou XJ, Fielman BA, Lloyd DM, et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006 Jul; 50(7): 2309–15PubMedCrossRefGoogle Scholar
  31. 31.
    Zhou X, Pietropaolo K, Becker M, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir [abstract no. 1782 plus poster]. Digestive Disease Week; 2007 May 19–24; Washington DCGoogle Scholar
  32. 32.
    Zhou XJ, Lim SG, Lloyd DM, et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006 Mar; 50(3): 874–9PubMedCrossRefGoogle Scholar
  33. 33.
    Zhou XJ, Myers M, Chao G, et al. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function [abstract no. 1166]. Hepatology 2004 Oct; 40 (4 Suppl. 1): 672Google Scholar
  34. 34.
    Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother 2006 May; 50(5): 1721–6PubMedCrossRefGoogle Scholar
  35. 35.
    Data on file. Novartis Pharmaceuticals Corporation, 2007Google Scholar
  36. 36.
    Lai C-L, Gane E, Liaw Y-F, et al. Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) [abstract no. 92]. Hepatology 2005 Oct; 42 (4 Suppl. 1): 232A–3A. Plus oral presentation at The Liver Meeting; 2005 Nov 11–15; San Francisco (CA)Google Scholar
  37. 37.
    Bzowej N, Lai C, Gane E, et al. Phase III comparison of telbivudine vs lamivudine in patients with chronic hepatitis B: efficacy, safety, and predictors of response at 1 year [abstract no. 482]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): A765–A766. Plus oral presentation at Digestive Disease Week; 2006 May 20–25; Los Angeles (CA)Google Scholar
  38. 38.
    Rasenack J, Poynard T, Lai C-L, et al. Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines [abstract plus poster]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11–15; BarcelonaGoogle Scholar
  39. 39.
    Poynard T, Chutaputti A, Hwang SG, et al. Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study [abstract]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11–15; BarcelonaGoogle Scholar
  40. 40.
    Han S, Lai C, Gane E, et al. Telbivudine GLOBE trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B [abstract no. S1777 plus poster]. Digestive Disease Week; 2007 May 19–24; Washington DCGoogle Scholar
  41. 41.
    Gane E, Lai C-L, Min A, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study [abstract and poster]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11–15; BarcelonaGoogle Scholar
  42. 42.
    Jia JD, Hou JL, Yin YK, et al. The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52 [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2007 May; 15(5): 342–5PubMedGoogle Scholar
  43. 43.
    Wang Y, Jia J, Hou J, et al. A phase III comparative trial of telbivudine vs lamivudine in Chinese patients with chronic hepatitis B: two-year results [abstract no. S1768 plus poster]. Digestive Disease Week; 2007 May 19–24; Washington DCGoogle Scholar
  44. 44.
    Safadi R, Xie Q, Chen Y, et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24 [abstract plus poster]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11–15; BarcelonaGoogle Scholar
  45. 45.
    Bzowej N, Marcellin P, Chan H, et al. A randomized trial of telbivudine vs adefovir for HBeAg-positive chronic hepatitis B: efficacy through week 76, predictors of response and effects of switching to telbivudine [abstract no. S1774 plus poster]. Digestive Disease Week; 2007 May 19–24; Washington DCGoogle Scholar
  46. 46.
    Marcellin P, Chan HLY, Lai C-L, et al. 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine [abstract]. 42nd Annual Meeting of the European Association for the Study of the Liver; 2007 Apr 11–15; BarcelonaGoogle Scholar
  47. 47.
    Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Saf 2000 Dec; 23(6): 467–81PubMedCrossRefGoogle Scholar
  48. 48.
    GlaxoSmithKline Research. Epivir-HBV® (lamivudine). US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_epivir_hbv.pdf [Accessed 2007 Jul 29]
  49. 49.
    Gilead Sciences Inc. Hepsera® (adefovir dipivoxil). US prescribing information [online]. Available from URL: http://www.hepsera.com/pdf/GIL214-07_Hepsera_PDF.8.pdf [Accessed 2007 Jul 29]

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations